Articles from Osage University Partners

The Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund) today announced its investment in Emvena Therapeutics, a biotechnology company developing mRNA medicines designed to deliver treatments directly to the placenta to address serious maternal and fetal conditions. Emvena is the first company launched and financed by the PxB Fund, which supports the translation of promising University of Pennsylvania research for the advancement of human health.

Osage University Partners (OUP) today announced the appointment of Gibb Witham as Venture Partner, further strengthening OUP’s commitment to scaling the most transformational and disruptive deep technology-based innovations.

The University of Pennsylvania (“Penn”), BioNTech SE (“BioNTech”), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (“PxB Fund”), a dedicated venture capital fund focused on early-stage life science companies originating from Penn. The joint effort will provide additional fuel to advance Penn discoveries into products that benefit patients across the world, following a decade in which the university’s research teams have spawned 45 FDA approvals for transformative vaccines and novel medical treatments such as CAR T cell therapy, and garnered a Nobel Prize and four Breakthrough Prizes for Life Sciences.

OUP (Osage University Partners), a venture capital firm that invests in startups commercializing breakthrough research, today announced the promotions of Manny Stockman, PhD, to Managing Partner, Mitra Miri, PhD, to Partner, and Beth Grafstrom to SVP Finance.